Growth & profitability
- Revenue has grown 48.0% per year over the past 5 years.
Financial health
- Operating income covered interest expense -17.2× in the latest year.
ABVC Financials ABVC BIOPHARMA, INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $296000 | -$8M | 0.0% | -2416.0% | — | — | $681480 |
| 2024 | $200000 | -$5M | 254.4% | -2352.6% | — | — | $248382 |
| 2023 | — | -$8M | — | — | -$4M | — | $60155 |
| 2022 | — | -$16M | — | — | -$8M | — | $85265 |
| 2021 | — | -$13M | — | — | -$8M | — | $6M |
| 2020 | — | -$11M | — | — | — | — | $4M |
| 2019 | — | -$4M | — | — | — | — | $144295 |
| 2018 | — | -$6M | — | — | — | — | $226688 |
| 2017 | — | -$4M | — | — | — | — | $350257 |
| 2017 | — | -$4M | — | — | — | — | $204851 |
| 2016 | — | -$11M | — | — | — | — | $173537 |
| 2015 | $50M | — | 0.0% | 0.0% | — | — | $423965 |
| 2015 | — | -$32281 | — | — | — | — | $994830 |
| 2014 | — | -$23235 | — | — | — | — | $0 |
| 2014 | — | -$70 | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$2M | — | — | — | — | $140324 |
| Dec '25 | -$499950 | -$4M | 0.0% | 599.0% | — | — | $681480 |
| Sep '25 | — | -$2M | — | — | — | — | $192068 |
| Jun '25 | — | -$2M | — | — | — | — | $388251 |
| Mar '25 | — | -$842075 | — | — | — | — | $152206 |
| Dec '24 | — | -$731574 | — | — | — | — | $248382 |
| Sep '24 | — | -$394769 | — | — | — | — | $137344 |
| Jun '24 | — | -$942336 | — | — | — | — | $124296 |
| Mar '24 | — | -$3M | — | — | — | — | $30489 |
| Dec '23 | — | -$383328 | — | — | -$430463 | — | $60155 |
| Sep '23 | — | -$3M | — | — | — | — | $500069 |
| Jun '23 | — | -$2M | — | — | — | — | $99290 |
| Mar '23 | — | -$2M | — | — | — | — | $1M |
| Dec '22 | — | -$5M | — | — | -$461158 | — | $85265 |
| Sep '22 | — | -$4M | — | — | -$518061 | — | $1M |
| Jun '22 | — | -$2M | — | — | -$3M | — | $3M |
| Mar '22 | — | -$6M | — | — | -$3M | — | $3M |
| Dec '21 | — | -$8M | — | — | -$3M | — | $6M |
| Sep '21 | — | -$2M | — | — | — | — | $4M |
| Jun '21 | — | -$2M | — | — | — | — | $924841 |
Valuation over time
How the market has priced ABVC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 76.1× (Dec '24) to 126.5× (Jun '26).
P/S
Frequently asked questions
Is ABVC growing its revenue and profit?
Over the past 5 years, ABVC BIOPHARMA, INC.'s revenue has grown 48.0% per year. These are computed facts, not advice.
How much debt does ABVC have?
As of FY2025, ABVC BIOPHARMA, INC. reported — of total debt against $681480 of cash; operating income covered interest expense -17.2×.
What is ABVC's profit margin?
In FY2025, gross margin was —, operating margin -2416.0%, and net margin -2671.8%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.